Abstracts tagged "mouse model and systemic sclerosis"

Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Clarissa Corinaldesi¹, Yasser M El-Sherbiny², Gemma Migneco³, Rebecca Ross¹, Steve Holmes⁴, Clive McKimmie⁵ and Francesco Del Galdo¹, ¹Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Capella Biosciences, LTD, London, United Kingdom, ⁵Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
Abstract Number: 26 • 2017 ACR/ARHP Annual Meeting
Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Yoshihide Asano³, Yutaka Kazoe⁴, Kazuma Mawatari⁴, Takehiko Kitamori⁴ and Shinichi Sato⁵, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁵Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Recent studies have indicated that B cells play critical roles in systemic autoimmunity and disease expression through various functions such as induction of the…
Abstract Number: 1845 • 2016 ACR/ARHP Annual Meeting
TGF-β-Induced Tissue Fibrosis Is Abrogated in Mice Containing a Constitutive Genetic Deletion of Nox4 (Nox4 knockout)
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Excessive deposition of collagen and other connective tissue components in the skin and multiple internal organs is characteristic of Systemic Sclerosis (SSc). Besides the…
Abstract Number: 2150 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis
Matthieu Ponsoye¹, Camelia Frantz², Nadira Ruzehaji³, Muriel Elhai⁴, Barbara Ruiz¹, Anne Cauvet¹, Yannick Allanore⁵ and Jerome Avouac⁴, ¹INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³INSERM U1016, Paris Descartes University, Paris, France, ⁴Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Early stages of systemic sclerosis (SSc) are characterized by inflammatory skin infiltrates mainly composed of activated T cells. Cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) is…
Abstract Number: 3001 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Jerome Avouac¹, Lucille Desallais², Maxime Fréchet³, Muriel Elhai³, Jean François Zagury² and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, ³INSERM U1016, Cochin Institute, Paris, France
Background/Purpose: Interleukin 6 (IL-6) is a pleiotropic cytokine involved in inflammatory and autoimmune processes. Preliminary data have suggested that IL-6 might contribute to systemic sclerosis…
Abstract Number: 967 • 2014 ACR/ARHP Annual Meeting
Mir-145 Protects Against Skin Fibrosis in Vivo by targeting TGF-β Signaling
Serena Vettori^1,2, Christian Beyer³, Matthias Brock¹, Naoki Iwamoto¹, Britta Maurer¹, Michelle Trenkmann¹, Astrid Jüngel¹, Renate E. Gay¹, Maurizio Calcagni⁴, Gabriele Valentini⁵, Steffen Gay¹, Joerg H. W. Distler³ and Oliver Distler¹, ¹Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ²Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland, ⁵Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose In vitro, miR-145 exerts anti-fibrotic effects in systemic sclerosis (SSc) by downregulating TGF-β signaling. In turn, ectopic TGF-β downregulates miR-145 thereby optimizing TGF-β signaling…
Abstract Number: 2567 • 2013 ACR/ARHP Annual Meeting
Cadherin-11 Regulates Pulmonary Fibrosis In Bleomycin-Induced Lung Injury
Mesias Pedroza, Anuh T. George and Sandeep K. Agarwal, Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Pulmonary fibrosis (PF) is the leading cause of death in systemic sclerosis. Pathologically, PF is characterized by an aberrant wound healing repair mechanism leading…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].